[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-460827-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-460827-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","management-of-infections-caused-by-carbapenemase-producing-enterobacterales-in-france-a-real-world-study","Management of infections caused by carbapenemase-producing Enterobacterales in France - a real-world study","","Carbapenemase-producing Enterobacterales (CPE) represent a major public health threat with limited therapeutic options and high mortality. This multicentre observational cross-sectional study assessed management of confirmed CPE infections across 31 French hospitals from September 2021 to March 2023, examining clinical practice, treatment regimens, and concordance with European and international guidelines. Of 6936 screened patients, 96 were included; outcomes were driven mainly by patient comorbidity burden and septic shock, despite low empirical appropriateness, especially for NDM.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/management-of-infections-caused-by-carbapenemase-producing-enterobacterales-in-france-a-real-world-study/460827/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/management-of-infections-caused-by-carbapenemase-producing-enterobacterales-in-france-a-real-world-study/460827.png","ImageObject",300,407,{"name":42,"@type":43},"Connor ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of the study on CPE infections in France?","Question",{"text":63,"@type":64},"To provide a multicentre snapshot of how CPE infections are managed in France, assess current clinical practices, and evaluate whether management aligns with international guidelines.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which carbapenemase types were most common among the included patients?",{"text":68,"@type":64},"OXA-48-like carbapenemases were predominant (50%), followed by New Delhi metallo-β-lactamase, NDM (38%).",{"name":70,"@type":61,"acceptedAnswer":71},"What factors were associated with 30-day mortality, and did treatment timing predict death?",{"text":72,"@type":64},"30-day mortality was associated with comorbidity burden and septic shock. Neither time to appropriate therapy nor therapy appropriateness independently predicted death.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},460827,1791366139,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","JAC Antimicrob Resist  \n[https://doi.org/10.1093/jacamr/dlaf260](https://doi.org/10.1093/jacamr/dlaf260)  \nJACAntimicrobial Resistance  \nManagement of infections caused by carbapenemase-producing Enterobacterales in France: a real-world study  \nB. Pilmis1,2,3, L. Escaut4, M. Seguret5, L. Weber5, F. Bussy6, S. Figueiredo5 and L. Dortet  3,6,7*  \n1Department of Clinical Microbiology, Saint-Joseph & Marie-Lannelongue Hospitals, Paris, France; 2Micalis Institute UMR 1319, Université Paris-Saclay, INRAe, AgroParisTech, Orsay, France; 3Faculty of Medicine, Team‘Resist’ UMR1184 ‘Immunology of Viral, Auto-Immune, Hematological, and Bacterial Diseases (IMVA-HB),’ INSERM, Université Paris-Saclay, CEA, Le Kremlin-Bicêtre, France; 4Department of Infectious and Tropical Diseases, Assistance Publique–Hôpitaux de Paris, Bicêtre Hospital, Paris-Saclay University, Le Kremlin-Bicêtre, France; 5Department of Anesthesia and Surgical Intensive Care, Bicêtre Hospital, Paris-Saclay University, Assistance Publique–Hôpitaux de Paris, Le Kremlin-Bicêtre, France; 6Department of Bacteriology-Hygiene, Bicêtre Hospital, Assistance Publique–Hôpitaux de Paris, Faculty of Medicine and Paris-Sud University, le Kremlin-Bicêtre, France; 7Associated French National Reference Center for Antibiotic Resistance: Carbapenemase-Producing Enterobacterales, Le Kremlin-Bicêtre, France  \n*Corresponding author. E-mail: [laurent.dortet@aphp.fr](laurent.dortet@aphp.fr)  \nReceived 6 October 2025; accepted 12 December 2025  \nBackground: Carbapenemase-producing Enterobacterales (CPE) are a significant public health concern, with limited treatment options and high mortality rates. The epidemiology and management of CPE infections in France remain insufficiently documented.  \nObjectives: To provide a multicentre snapshot of the management of CPE infections in France, assess current clinical practices and evaluate their alignment with international guidelines.  \nMethods: We conducted a multicenter, observational, cross-sectional study across 31 French hospitals between September 2021 and March 2023. Adult patients with confirmed CPE infections were included. Clinical and microbiological data were collected retrospectively. Treatment regimens were analysed, and therapeutic appropriateness was assessed based on European and international guidelines.  \nResults: Among 6936 screened patients, 96 met the inclusion criteria. The most frequently isolated pathogens were Klebsiella pneumoniae (42%), Escherichia coli (18%) and Enterobacter cloacae complex (16%) . OXA-48-like carbapenemases were predominant (50%), followed by New Delhi metallo-β-lactamase (NDM) (38%) . Initial empirical therapy was administered in 92.7% of patients overall; appropriateness was 50% in OXA-48-like infections and 25.5% in NDM infections. On multivariable analysis, 30-day mortality (34%) was associated with comorbidity burden and septic shock, whereas neither time to appropriate therapy nor therapy appropriateness independently predicted death. These data suggest outcomes were mainly driven by patient factors and severity, despite low empirical appropriateness—particularly for NDM—which supports efforts to improve early targeting through rapid diagnostics.  \nConclusions: This study highlights the challenges associated with CPE infections, including high mortality and frequent inappropriate empirical therapy. Our findings emphasize the need for optimized antimicrobial stewardship and rapid microbiological diagnostics to improve patient outcomes.  \nIntroduction  \nMultidrug-resistant organisms, particularly carbapenemaseproducing Enterobacterales (CPE), are an increasing public health concern worldwide and represent one of the most concerning issues in the field of antimicrobial resistance.1 There are notable geographical disparities in the types of carbapenemase enzymes  \nand resistance mechanisms observed globally. The three main types of carbapenemases are Klebsiella pneumoniae carbapenemase (KPC), New Delhi metal","cbCaiphPnuOnk2ab","https://ap.wps.com/l/cbCaiphPnuOnk2ab","pdf",587911,"English","# Background\n# Objectives\n# Methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What is the main purpose of the study on CPE infections in France?\",\"answer\":\"To provide a multicentre snapshot of how CPE infections are managed in France, assess current clinical practices, and evaluate whether management aligns with international guidelines.\"},{\"question\":\"Which carbapenemase types were most common among the included patients?\",\"answer\":\"OXA-48-like carbapenemases were predominant (50%), followed by New Delhi metallo-β-lactamase, NDM (38%).\"},{\"question\":\"What factors were associated with 30-day mortality, and did treatment timing predict death?\",\"answer\":\"30-day mortality was associated with comorbidity burden and septic shock. Neither time to appropriate therapy nor therapy appropriateness independently predicted death.\"}]","Management of infections caused by carbapenemase-producing Enterobacterales in France - a real-world study | PDF",1790759745,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/137b9ae2c4f4fc0ccbcb2fbbf7c2763c.webp",983,1269,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/4b454a224e4ffd38bf3bf53d40947e6c.webp",982,1268,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/4c34aba2e38d1d6b0cf512372d33f9c3.webp",981,1266,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/8aa65a5b438dfa5a83b8fd9675155480.webp",980,1265]